Literature DB >> 16884835

Mumps vaccine virus strains and aseptic meningitis.

Marie-Claude Bonnet1, Anil Dutta, Clement Weinberger, Stanley A Plotkin.   

Abstract

Mumps immunization can easily be included in national schedules, particularly if combined with measles or measles and rubella vaccines, but debate continues concerning the relative safety of various licensed mumps vaccine strains. The opportunities for control of mumps are also being affected by differences in the cost of the vaccines prepared with different strains of mumps virus. The present report evaluates available data on the association of the Urabe and other strains of mumps vaccine with the occurrence of aseptic meningitis. We also review the comparative immunogenicity and efficacies of the most widely used mumps vaccines in controlled clinical trials and field evaluations, and briefly examine relative cost as it relates to the implementation of national immunization programs. We conclude that extensive experience with the most widely used mumps vaccine strains in many countries has shown that the risk-benefit ratio of live mumps vaccines is highly favourable for vaccination, despite the occasional occurence of aseptic meningitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884835     DOI: 10.1016/j.vaccine.2006.06.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

Authors:  S Elizabeth Williams; Nicola P Klein; Neal Halsey; Cornelia L Dekker; Roger P Baxter; Colin D Marchant; Philip S LaRussa; Robert C Sparks; Jerome I Tokars; Barbara A Pahud; Laurie Aukes; Kathleen Jakob; Silvia Coronel; Howard Choi; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

2.  Generation and propagation of recombinant mumps viruses exhibiting an additional U residue in the homopolymeric U tract of the F gene-end signal.

Authors:  Christian J Sauder; Laurie Ngo; Vahan Simonyan; Yu Cong; Cheryl Zhang; Malen Link; Tahir Malik; Steven A Rubin
Journal:  Virus Genes       Date:  2015-05-12       Impact factor: 2.332

3.  Characterization of large mumps outbreak among vaccinated Palestinian refugees.

Authors:  Musa Y Hindiyeh; Yair Aboudy; Mahmoud Wohoush; Lester M Shulman; Daniela Ram; Tal Levin; Tamar Frank; Flavia Riccardo; Mohamad Khalili; Elias-Shlash Sawalha; Maysoun Obeidi; Guido Sabatinelli; Zehava Grossman; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

4.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

5.  Anti-mumps virus activity by extracts of Mimosa pudica, a unique Indian medicinal plant.

Authors:  Jeevan Malayan; Balaji Selvaraj; Aparna Warrier; Sambantham Shanmugam; Manikannan Mathayan; Thangam Menon
Journal:  Indian J Virol       Date:  2013-08-10

6.  Relaxation of purifying selection on live attenuated vaccine strains of the family Paramyxoviridae.

Authors:  Austin L Hughes
Journal:  Vaccine       Date:  2009-02-03       Impact factor: 3.641

7.  Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.

Authors:  Silvia Perez-Vilar; Daniel Weibel; Miriam Sturkenboom; Steven Black; Christine Maure; Jose Luis Castro; Pamela Bravo-Alcántara; Caitlin N Dodd; Silvana A Romio; Maria de Ridder; Swabra Nakato; Helvert Felipe Molina-León; Varalakshmi Elango; Patrick L F Zuber
Journal:  Vaccine       Date:  2017-05-27       Impact factor: 3.641

Review 8.  Methodological frontiers in vaccine safety: qualifying available evidence for rare events, use of distributed data networks to monitor vaccine safety issues, and monitoring the safety of pregnancy interventions.

Authors:  Caitlin Dodd; Nick Andrews; Helen Petousis-Harris; Miriam Sturkenboom; Saad B Omer; Steven Black
Journal:  BMJ Glob Health       Date:  2021-05

Review 9.  Knowledge gaps persist and hinder progress in eliminating mumps.

Authors:  R Ramanathan; E A Voigt; R B Kennedy; G A Poland
Journal:  Vaccine       Date:  2018-05-18       Impact factor: 4.169

10.  Establishment of a standard seed lot system of an Iranian Mumps virus strain; RS-12, for mass production of mumps and MMR vaccines.

Authors:  M K Shahkarami; T Mokhtari Azad; K Aghaiypour; A Shafyi; M Taqavian; A Mohammadi
Journal:  Iran Red Crescent Med J       Date:  2012-09-30       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.